RecruitMe Clinical Trial

A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)
A study for patients with advanced hepatocellular carcinoma using study drug pembrolizumab
Sponsor:Merck Sharp & Dohme Corp.
Enrolling:Male and Female Patients
Age Range:Between 18 and 99 years old
IRB Number:AAAQ8401
U.S. Government ID:NCT02702414
Contact: Gulam Manji: 212-305-0592 / gam2140@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to test the safety, tolerability, and anti-tumor activity of the research study drug, Pembrolizumab (also known as MK-3475) in subjects with advanced hepatocellular carcinoma (a type of liver cancer also referred to as HCC) who have taken sorafenib.

This study is closed
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Gulam Manji
Email: gam2140@cumc.columbia.edu
Phone: 212-305-0592